Bedrocan expands medical cannabis production to Denmark

Dutch medical cannabis producer Bedrocan is opening a new facility in Denmark to meet patient demand across Europe. Bedrocan has been the only medical cannabis producer in the Netherlands since 2003 and has now announced that it will build new facilities to manufacture its products in Denmark. The company claims that the new facilities will be GMP certified and will be located in Køge, near Copenhagen, which will allow it to expand production capacity to respond to the growing international demand for its products.

*Article originally published by journalist Sarah Sinclair at CannabisHealth.

Bedrocan's products are used by patients on prescription and as pharmaceutical raw materials and active pharmaceutical ingredients (API's) by researchers and pharmaceutical companies in many countries around the world.

It currently operates two in-house production facilities, a plant research and development facility and a laboratory in the Netherlands. However, under the current legal structure, Bedrocan products are only available through the Dutch Office of Medical Cannabis (OMC), which is part of the Ministry of Health.

With its Danish operation, Bedrocan hopes to significantly improve the availability of its products to patients around the world, with the freedom to conduct business directly with other commercial entities.

The new facility is expected to be operational by the end of 2023, with around 40 employees on board. It will start with the production of well-known Bedrocan varieties, including Bedrocan and Bediol oils, as well as a new high-CBD variety, with products initially intended to supply the European market.

Bedrocan CEO Jaap Erkelens said the move would benefit patients as access to its products would be less dependent on "political agreements". “At Bedrocan, the patient comes first,” Erkelens said in a release to Cannabis Health.

“The expansion into Denmark will enable us to respond even better in the future. The availability of Bedrocan products in Europe will soon be less dependent on political agreements between countries. This improves security of supply, which is good for all patients.”

Last year, British company Target Healthcare guaranteed a UK license to produce Bedrocan oils for UK patients.